Phosphoglucosamine mutase (GlmM)

Phosphoglucosamine mutase (GlmM) is an essential bacterial enzyme belonging to the alpha-D-phosphohexomutase superfamily that catalyzes the reversible interconversion of glucosamine-6-phosphate and glucosamine-1-phosphate [5][12]. This reaction constitutes a vital step in the hexosamine biosynthetic pathway, leading to the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a key building block for bacterial peptidoglycan and lipopolysaccharides [4][9]. Because GlmM is indispensable for maintaining the integrity of the bacterial cell wall and performs a specific reaction not found in humans, it represents a promising target for the development of highly selective antibacterial agents [1][3]. Studies have demonstrated that GlmM is required for the growth, morphology, and biofilm formation of various pathogens, including Mycobacterium tuberculosis, Staphylococcus aureus, and Helicobacter pylori [4][7][15]. While no GlmM-targeted drugs are currently approved for clinical use, experimental inhibitors have shown potential in reducing bacterial viability and sensitizing pathogens to existing antibiotics like isoniazid and ethambutol [3][4]. The enzyme's unique specificity for non-acetylated glucosamine phosphates provides a significant therapeutic window, as the closest human orthologs utilize different substrates, such as N-acetylated sugars or glucose-based phosphates [4][8].

Other names

GlmM proteinalpha-D-glucosamine 1,6-phosphomutasePNGMureCfemR315Rv3441c

Inhibition of GlmM prevents the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate, thereby depleting the pool of UDP-N-acetylglucosamine required for peptidoglycan and lipopolysaccharide synthesis, which leads to compromised bacterial cell wall integrity and cell death [1][4].